<unk>  inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin. It is mostly eliminated by being taken up into cells via endocytosis and being broken down inside them.
Secukinumab
Emapalumab
Evolocumab
Olaratumab
Sarilumab
Burosumab
Ustekinumab
Avelumab